

RECEIVED
CENTRAL FAX CENTER

APR 21 2009

Hiroshi Inooka et al.
USSN 10/594,773 – Filing Date: September 29, 2006
Page 2

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (currently amended) A[n] ~~agent~~ method for improving the blood stability of an ~~mammalian~~ endogenous ~~ligand~~ GLP-1 produced in a ~~mammal~~ mammalian body, which comprises administering to the mammal an effective amount of an antibody that has an affinity to the endogenous ~~ligand~~ GLP-1 but does not neutralize the same substantially, without administration of GLP-1 from outside the body.
2. (currently amended) The ~~agent~~ method of claim 1, wherein the improved blood stability of the endogenous ~~ligand~~ GLP-1 results in the enhancement of ~~receptor activity-regulatory action thereof~~ the activity of a GLP-1 receptor.
3. (previously presented) The ~~agent~~ method of claim 1, wherein the neutralizing activity of the antibody is about 80% or less.
4. (currently amended) The ~~agent~~ method of claim 1, wherein the blood concentration of the endogenous ~~ligand~~ GLP-1 becomes about twice or more compared to the case where the antibody is not administered.
5. (currently amended) The ~~agent~~ method of claim 1, wherein the blood half-life of the complex of the endogenous ~~ligand~~ GLP-1 and the antibody is about twice or more as that of the endogenous ~~ligand~~ GLP-1 alone.
- 6 - 13. (canceled) The ~~agent~~ method of claim 1, wherein the blood half-life of the

BOS2 733213.1

Hiroshi Inooka et al.
USPN 10/594,773 – Filing Date: September 29, 2006
Page 3

free endogenous ligand is about one week or less.

14. (currently amended) The ~~agent~~ method of claim 1, which is for the prophylaxis and/or treatment of a metabolic disease ~~in which an increased blood concentration and/or a prolonged blood half-life of the endogenous ligand are/is effective for the prophylaxis and/or treatment thereof.~~

15. (currently amended) The ~~agent~~ method of claim 14, wherein the ~~disease is selected from the group consisting of metabolic disease, bone and joint disease, cardiovascular disease, cranial nerve disease, infectious disease, cancer, blood disorder, urologic disease, infertility/erectile dysfunction, deficient growth and immunodeficiency~~ is diabetes.

16 -17. (canceled)

BOS2 733213.1